Anxiolytic-like Effect of Inhalation of Essential Oil from Lavandula officinalis : Investigation of Changes in 5-HT Turnover and Involvement of Olfactory Stimulation
Free accessResearch articleFirst published online July, 2014
Anxiolytic-like Effect of Inhalation of Essential Oil from Lavandula officinalis : Investigation of Changes in 5-HT Turnover and Involvement of Olfactory Stimulation
Essential oil extracted from Lavandula officinalis (LvEO) has a long history of usage in anxiety alleviation with good evidence to support its use. However, findings and information regarding the exact pathway involved and mechanism of action remain inconclusive. Therefore, we aimed to (1) reveal the influence of olfactory stimulation, and (2) determine whether the serotonergic system is involved in the anxiolytic effect of LvEO when it is inhaled. To this end, we first compared the anxiety-related behaviors of normosmic and anosmic mice. LvEO inhalation caused notable elevation in anxiety-related parameters with or without olfactory perception, indicating that olfactory stimulation is not necessarily required for LvEO to be effective. Neurochemical analysis of the serotonin (5-HT) turnover rate, accompanied by EPM testing, was then performed. LvEO significantly increased the striatal and hippocampal levels of 5-HT and decreased turnover rates in accordance with the anxiolytic behavioral changes. These results, together with previous findings, support the hypothesis that serotonergic neurotransmission plays a certain role in the anxiolytic properties of LvEO.
PerryR., TerryR., WatsonL.K., ErnstE. (2012) Is lavender an anxiolytic drug? A systematic review of randomised clinical trials. Phytomedicine: International Journal of Phytotherapy and Phytopharmacology, 19, 825–835.
2.
(a) Souto-MaiorF.N., de CarvalhoF.L., de MoraisL.C., NettoS.M., de SousaD.P., de AlmeidaR.N. (2011) Anxiolytic-like effects of inhaled linalool oxide in experimental mouse anxiety models. Pharmacology, Biochemistry, and Behavior, 100, 259–263; (b) Bradley BF, Starkey NJ, Brown SL, Lea RW. (2007) Anxiolytic effects of Lavandula angustifolia odour on the Mongolian gerbil elevated plus maze. Journal of Ethnopharmacology, 111, 517–525; (c) Takahashi M, Satou T, Ohashi M, Hayashi S, Sadamoto K, Koike K. (2011) Interspecies comparison of chemical composition and anxiolytic-like effects of lavender oils upon inhalation. Natural Product Communications, 6, 1769–1774.
3.
(a) ShawD., NorwoodK., LeslieJ.C. (2011) Chlordiazepoxide and lavender oil alter unconditioned anxiety-induced c-fos expression in the rat brain. Behavioural Brain Research, 224, 1–7; (b) Shaw D, Annett JM, Doherty B, Leslie JC. (2007) Anxiolytic effects of lavender oil inhalation on open-field behaviour in rats. Phytomedicine: International Journal of Phytotherapy and Phytopharmacology, 14, 613–620; (c) Chioca LR, Antunes VDC, Ferro MM, Losso EM, Andreatini R. (2013) Anxiolytic-like effect of lavender essential oil inhalation in mice: Participation of serotonergic but not GABAA/benzodiazepine neurotransmission. Journal of Ethnopharmacology, 147, 412–418; (d) Kasper S, Gastpar M, Muller WE, Volz HP, Moller HJ, Dienel A. (2010) Silexan, an orally administered lavandula oil preparation, is effective in the treatment of ‘subsyndromal’ anxiety disorder: A randomized, double-blind, placebo controlled trial. International Clinical Psychopharmacology, 25, 277–287.
4.
WoelkH., SchlafkeS. (2010) A multi-center, double-blind, randomised study of the lavender oil preparation silexan in comparison to lorazepam for generalized anxiety disorder. Phytomedicine: International Journal of Phytotherapy and Phytopharmacology, 17, 94–99.
5.
(a) BradleyB.F., BrownS.L., ChuS., LeaR.W. (2009) Effects of orally administered lavender essential oil on responses to anxiety-provoking film clips. Human Psychopharmacology, 24, 319–330; (b) Umezu T, Nagano K, Ito H, Kosakai K, Sakaniwa M, Morita M. (2006) Anticonflict effects of lavender oil and identification of its active constituents. Pharmacology, Biochemistry, and Behavior, 85, 713–721.
6.
MaximinoC. (2012) Serotonin and anxiety: Neuroanatomical, pharmacological, and functional aspects.Springer, New York.
7.
(a) BarretJ.E. (1993) 5-HT receptors as a target for the development of novel anxiolytic drugs: Models, mechanisms and future directions. Psychopharmacology, 112, 1–12; (b) Griebel G. (1995) 5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders: More than 30 years of research. Pharmacology & Therapeutics, 65, 319–395; (c) Reichenberg LW. (2013) DSM-5 essentials. John Wiley & Sons, Incorporated, New York; (d) Tsuji M, Takeda H, Matsumiya T. (2000) Multiplicity of anxiety and serotonin nervous system. Folia Pharmacol Jpn, 115, 29–38.
8.
(a) UmezuT. (2009) The recent trend of experimental studies on the pharmacological actions of plant-derived essential oils on the central nervous system. Japanese Journal of Aromatherapy, 9, 1–20; (b) Barton DA, Esler MD, Dawood T, Lambert EA, Haikerwal D, Brenchley C. (2008) Elevated brain serotonin turnover in patients with depression: Effect of genotype and therapy. Archives of General Psychiatry, 65, 38–46.
9.
McBlaneJ.W., HandleyS.L. (1994) Effects of two stressors on behaviour in the elevated X-maze: Preliminary investigation of their interaction with 8-OH-DPAT. Psychopharmacology, 116, 173–182.
10.
MullerC.P., JacobsB. (2009) Handbook of the behavioral neurobiology of serotonin.Academic Press Inc., London.
11.
(a) McBrideK., SlotnickB., MargolisF.L. (2003) Does intranasal application of zinc sulfate produce anosmia in the mouse? An olfactometric and anatomical study. Chemical Senses, 28, 659–670; (b) Wall PL, Botly LC, Black CK, Shettleworth SJ. (2004) The geometric module in the rat: Independence of shape and feature learning in a food finding task. Learning & Behavior, 32, 289–298.
12.
(a) ChiocaL.R., AntunesV.D.C., FerroM.M., LossoE.M., AndreatiniR. (2013) Anosmia does not impair the anxiolytic-like effect of lavender essential oil inhalation in mice. Life Sciences, 92, 971–975; (b) Hogg S. (1996) A review of the validity and variability of the elevated plus-maze as an animal model of anxiety. Pharmacology, Biochemistry, and Behavior, 54, 21–30; (c) Harkin AK, Kell JP, Leonard BE. (2003) A review of the relevance and validity of olfactory bulbectomy as a model of depression. Clinical Neuroscience Research, 3, 253–264.
13.
SongC.L.B. (2005) The olfactory bulbectomised rat as a model of depression. Neuroscience &.Biobehavioral. Review, 29, 627–647.
14.
(a) ZuegerM., UraniA., ChourbajiS., ZacherC., RocheM., HarkinA. (2005) Olfactory bulbectomy in mice induces alterations in exploratory behavior. Neuroscience Letters, 374, 142–146; (b) Wieronska JM, Papp M, Pilc A. (2001) Effects of anxiolytic drugs on some behavioral consequences in olfactory bulbectomized rats. Polish Journal of Pharmacology, 53, 517–525.
15.
ButlerJ., TannianM., LeonardB.E. (1986) The chronic effects of desipramine and sertraline on platelet and synaptosomal 5HT uptake in olfactory bulbectomised rats. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 12, 585–594.
16.
YamaguchiT., YoshiokaM. (2007) Evaluation for anxiety-related behaviors in rodents. Folia Pharmacologica Japonica, 130, 105–111.
17.
(a) LimaL., SalazarM., TrejoE. (1993) Modulation of 5-HT1A receptors in the hippocampus and the raphe area of rats treated with clonazepam. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 17, 663–677; (b) Jenner P, Chadwick D, Reynolds EH, Marsden CD. (1975) Altered 5-HT metabolism with clonazepam, diazepam and diphenylhydantoin. Journal of Pharmacy and Pharmacology, 27, 707–710.
18.
ListerG.R., FileE.S. (1983) Changes in regional concentration in the rat brain of 5-hydroxytryptamine and 5-hydroxyindoleacetic acid during the development of tolerance to the sedative action of chlordiazepoxide. Journal of Pharmacy and Pharmacology, 35, 601–603.
19.
(a) LimaL., TrejoE., UrbinaM. (1995) Serotonin turnover rate, [3H] paroxetine binding sites, and 5-HT1A receptors in the hippocampus of rats subchronically treated with clonazepam. Neuropharmacology, 10, 1327–1333; (b) Trouvin JH, Gardier AM, Chanut E, Pages N, Jacquot C. (1993) Time course of brain serotonin metabolism after cessation of long-term fluoxetine treatment in the rat. Life Sciences, 52, PL187–92.
20.
(a) ButterweckV., BockersT., KorteB., WittkowskiW., WinterhoffH. (2002) Long-term effects of St. John's Wort and hypericin on monoamine levels in rat hypothalamus and hippocampus. Brain Research, 930, 21–29; (b) Hall LM, Anderson GM, Cohen DJ. (1995) Acute and chronic effects of fluoxetine and haloperidol on mouse brain serotonin and norepinephrine turnover. Life Sciences, 57, 791–801; (c) Pellow S, Chopin P, File SE, Briley M. (1985) Validation of open: closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. Journal of Neuroscience Methods, 14, 149–167; (d) Masuo Y, Morita M, Oka S, Ishido M. (2004) Motor hyperactivity caused by a deficit in dopaminergic neurons and the effects of endocrine disruptors: A study inspired by the physiological roles of PACAP in the brain. Regulatory Peptides, 123, 225–234.
21.
MurakamiS., ItohM.T. (2003) Removal of both antennae influences the courtship and aggressive behaviors in male crickets. Journal of Neurobiology, 57, 110–118.
